Psilocybin in the Treatment of Mental Disorders

Öz

Psilocybin is a classic serotonergic psychedelic substance that has shown promise in the treatment of mental disorders such as depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, eating disorders, and addiction. This review analyzes the current literature, addresses the therapeutic effects of psilocybin, its possible mechanisms, and ethical and legal issues regarding its clinical use. It also provides recommendations that will shed light on the future clinical applications of psilocybin-assisted therapies. This article aims to be a resource for researchers and clinicians who want to understand the potential of psilocybin and develop new treatment strategies in the field of mental health.

Anahtar Kelimeler

• Psychedelics
• Psilocybin
• Mental disorders
• Treatment

Ruhsal Bozuklukların Tedavisinde Psilosibin

Öz

Psilosibin, klasik bir serotonerjik psikedelik madde olup, depresyon, anksiyete, travma sonrası stres bozukluğu, obsesif kompulsif bozukluk, yeme bozuklukları ve bağımlılık gibi ruhsal bozuklukların tedavisinde umut vaat etmektedir. Bu derleme, mevcut literatürü analiz ederek, psilosibinin terapötik etkilerini, olası mekanizmalarını ve klinik kullanımına dair etik ve yasal konuları ele almaktadır. Ayrıca, psilosibin destekli terapilerin gelecekteki klinik uygulamalarına ışık tutacak öneriler sunulmaktadır. Bu makale, psilosibinin potansiyelini anlamak ve ruh sağlığı alanında yeni tedavi stratejileri geliştirmek isteyen araştırmacılar ve klinisyenler için bir kaynak olmayı amaçlamaktadır.

Anahtar Kelimeler

• Psikedelik
• Psilosibin
• Ruhsal bozukluklar
• Tedavi

Kaynakça

1. Andrews, C. M., Hall, W., Humphreys, K., & Marsden, J. (2024). Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis? Addiction. doi:10.1111/add.16575
2. Araújo, A. M., Carvalho, F., Bastos Mde, L., Guedes de Pinho, P., & Carvalho, M. (2015). The hallucinogenic world of tryptamines: an updated review. Arch Toxicol, 89(8), 1151-1173. doi:10.1007/s00204-015-1513-x
3. Barber, G. S., & Dike, C. C. (2023). Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry. Psychiatr Serv, 74(8), 838-846. doi:10.1176/appi.ps.20220525
4. Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep, 10(1), 2214. doi:10.1038/s41598-020-59282-y
5. Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O'Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., Tonigan, J. S., & Worth, L. (2022). Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA psychiatry, 79(10), 953-962. doi:10.1001/jamapsychiatry.2022.2096
6. Bonnieux, J. N., VanderZwaag, B., Premji, Z., Garcia-Romeu, A., & Garcia-Barrera, M. A. (2023). Psilocybin's effects on cognition and creativity: A scoping review. J Psychopharmacol, 37(7), 635-648. doi:10.1177/02698811231179801
7. Buntrock, C., Harrer, M., Sprenger, A. A., Illing, S., Sakata, M., Furukawa, T. A., Ebert, D. D., & Cuijpers, P. (2024). Psychological interventions to prevent the onset of major depression in adults: A systematic review and individual participant data meta-analysis. The Lancet Psychiatry, 11(12), 990–1001. doi:10.1016/S2215-0366(24)00345-6
8. Cahill, K., Stevens, S., & Lancaster, T. (2014). Pharmacological treatments for smoking cessation. JAMA, 311(2), 193–194. https://doi.org/10.1001/jama.2013.283787

9. Calder, A., Mock, S., Friedli, N., Pasi, P., & Hasler, G. (2023). Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms. Eur Neuropsychopharmacol, 75, 1-14. doi:10.1016/j.euroneuro.2023.05.008
10. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 3(7), 619-627. doi:10.1016/s2215-0366(16)30065-7
11. Conn, K., Milton, L. K., Huang, K., Munguba, H., Ruuska, J., Oldfield, B. J., & Foldi, C. J. (2024). Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms. Mol Psychiatry. doi:10.1038/s41380-024-02575-9
12. Coppola, M., Bevione, F., & Mondola, R. (2022). Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective? J Xenobiot, 12(1), 41-52. doi:10.3390/jox12010004
13. Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA psychiatry, 78(5), 481-489. doi:10.1001/jamapsychiatry.2020.3285
14. de Veen, B. T., Schellekens, A. F., Verheij, M. M., & Homberg, J. R. (2017). Psilocybin for treating substance use disorders? Expert Rev Neurother, 17(2), 203-212. doi:10.1080/14737175.2016.1220834
15. Demmler, R., Fricke, J., Dörner, S., Gressler, M., & Hoffmeister, D. (2020). S-Adenosyl-l-Methionine Salvage Impacts Psilocybin Formation in "Magic" Mushrooms. Chembiochem, 21(9), 1364-1371. doi:10.1002/cbic.201900649
16. Dos Santos, R. G., Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. (2021). The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. Risk Manag Healthc Policy, 14, 901-910. doi:10.2147/rmhp.S300656
17. Du, Y., Li, Y., Zhao, X., Yao, Y., Wang, B., Zhang, L., & Wang, G. (2023). Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity. Chin Med J, 136(24), 2983-2992. doi:10.1097/cm9.0000000000002647
18. Fang, S., Yang, X., & Zhang, W. (2024). Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. Front Psychiatry, 15,1359088, 1359088. doi:10.3389/fpsyt.2024.1359088
19. Feulner, L., Sermchaiwong, T., Rodland, N., & Galarneau, D. (2023). Efficacy and safety of psychedelics in treating anxiety disorders. Ochsner Journal, 23(4), 315–328. doi:10.31486/toj.23.0076
20. Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. (2020). The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res, 284, 112749. doi:10.1016/j.psychres.2020.112749
21. Heal, D. J., Smith, S. L., Belouin, S. J., & Henningfield, J. E. (2023). Psychedelics: Threshold of a Therapeutic Revolution. Neuropharmacology, 236, 109610. doi:10.1016/j.neuropharm.2023.109610
22. Hofmann, A., Heim, R., Brack, A., Kobel, H., Frey, A., Ott, H., Petrzilka, T., & Troxler, F. (1959). Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen. Helvetica Chimica Acta, 42(5), 1557–1572.doi:10.1002/hlca.19590420518
23. Johnson, M. W., & Griffiths, R. R. (2017). Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, 14(3), 734-740. doi:10.1007/s13311-017-0542-y
24. Kaminski, D., & Reinert, J. P. (2024). The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review. Ann Pharmacother, 58(8), 811-826. doi:10.1177/10600280231205645
25. Khan, A. J., Bradley, E., O'Donovan, A., & Woolley, J. (2022). Psilocybin for Trauma-Related Disorders. Curr Top Behav Neurosci, 56, 319-332. doi:10.1007/7854_2022_366
26. Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V., Ramaekers, J. G., & Mason, N. L. (2022). Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees. Front Psychiatry, 13, 883869. doi:10.3389/fpsyt.2022.883869
27. Koning, E., & Brietzke, E. (2023). Psilocybin-Assisted Psychotherapy as a Potential Treatment for Eating Disorders: a Narrative Review of Preliminary Evidence. Trends Psychiatry Psychother. doi:10.47626/2237-6089-2022-0597
28. Kraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2016). The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage Clin, 11, 53-60. doi:10.1016/j.nicl.2015.08.009
29. Lugo-Radillo A Md, P., & Cortes-Lopez, J. M. (2021). Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms. J Psychoactive Drugs, 53(2), 146-148. doi:10.1080/02791072.2020.1849879
30. Mahmood, Z. A. (2013). Bioactive Alkaloids from Fungi: Psilocybin 18. Hand Book of Natural Products.
31. Marks, M., Brendel, R. W., Shachar, C., & Cohen, I. G. (2024). Essentials of Informed Consent to Psychedelic Medicine. JAMA psychiatry, 81(6), 611-617. doi:10.1001/jamapsychiatry.2024.0184
32. MacCallum, C. A., Lo, L. A., Pistawka, C. A., & Deol, J. K. (2022). Therapeutic use of psilocybin: Practical considerations for dosing and administration. Frontiers in Psychiatry, 13, 1040217.
33. McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C., Harvey, I., Kious, B., Marks, M., Mithoefer, M., Nielson, E., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., Williams, M. T., & Yaden, D. B. (2024). Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Netw Open, 7(6), e2414650. doi:10.1001/jamanetworkopen.2024.14650
34. Metaxa, A. M., & Clarke, M. (2024). Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. Bmj, 385, e078084. doi:10.1136/bmj-2023-078084
35. Meyer, M., & Slot, J. (2023). The evolution and ecology of psilocybin in nature. Fungal Genet Biol, 167, 103812. doi:10.1016/j.fgb.2023.103812
36. Moreno, F. A., & Delgado, P. L. (1997). Hallucinogen-induced relief of obsessions and compulsions. American Journal of Psychiatry, 154(7), 1037–1038. https://doi.org/10.1176/ajp.154.7.1037
37. Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry, 67(11), 1735-1740. doi:10.4088/jcp.v67n1110
38. Nichols, D. E. (2012). Structure–activity relationships of serotonin 5-HT2A agonists. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling, 1(5), 559-579. doi:https://doi.org/10.1002/wmts.42
39. Nutt, D. J., Peill, J. M., Weiss, B., Godfrey, K., Carhart-Harris, R. L., & Erritzoe, D. (2024). Psilocybin and Other Classic Psychedelics in Depression. Curr Top Behav Neurosci, 66, 149-174. doi:10.1007/7854_2023_451
40. O'Leary, O. F., Dinan, T. G., & Cryan, J. F. (2015). Faster, better, stronger: towards new antidepressant therapeutic strategies. Eur J Pharmacol, 753, 32-50. doi:10.1016/j.ejphar.2014.07.046
41. Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci, 66(3), 418-434. doi:10.1111/j.1749-6632.1957.tb40738.x
42. Owe-Larsson, M., Kamińska, K., Buchalska, B., Mirowska-Guzel, D., & Cudnoch-Jędrzejewska, A. (2024). Psilocybin in pharmacotherapy of obsessive-compulsive disorder. Pharmacol Rep. doi:10.1007/s43440-024-00633-1
43. Peck, S. K., Shao, S., Gruen, T., Yang, K., Babakanian, A., Trim, J., Finn, D. M., & Kaye, W. H. (2023). Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med, 29(8), 1947-1953. doi:10.1038/s41591-023-02455-9
44. Prouzeau, D., Conejero, I., Voyvodic, P. L., Becamel, C., Abbar, M., & Lopez-Castroman, J. (2022). Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review. Current psychiatry reports, 24(10), 573-581. doi:10.1007/s11920-022-01361-0
45. Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., Mletzko, T., Nicholas, C. R., Hutson, P. R., Tarpley, G., Utzinger, M., Lenoch, K., Warchol, K., Gapasin, T., Davis, M. C., Nelson-Douthit, C., Wilson, S., Brown, C., Linton, W., Johnson, M. W., Ross, S., & Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843-853. doi:10.1001/jama.2023.14530
46. Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2021). A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT(2A) Receptor Density in the Pig Brain. Int J Mol Sci, 22(2). doi:10.3390/ijms22020835
47. Sahagún, B. d., Anderson, A. J., & Dibble, C. E. (1950). General history of the things of New Spain. Florentine Codex. Sayin, H. Ü. (2017). Psychoactive Plants Consumed in Religious Rituals: Common Archetypal Symbols & Figures in Myths & Religions. SexuS Journal, 2(5), 201-236.
48. Sharma, P., Nguyen, Q. A., Matthews, S. J., Carpenter, E., Mathews, D. B., Patten, C. A., & Hammond, C. J. (2023). Psilocybin history, action and reaction: A narrative clinical review. J Psychopharmacol, 37(9), 849-865. doi:10.1177/02698811231190858
49. Siegel, J. S., Daily, J. E., Perry, D. A., & Nicol, G. E. (2023). Psychedelic Drug Legislative Reform and Legalization in the US. JAMA psychiatry, 80(1), 77-83. doi:10.1001/jamapsychiatry.2022.4101
50. Siegel, J. S., Subramanian, S., Perry, D., Kay, B., Gordon, E., Laumann, T., Reneau, R., Gratton, C., Horan, C., Metcalf, N., Chacko, R., Schweiger, J., Wong, D., Bender, D., Padawer-Curry, J., Raison, C., Raichle, M., Lenze, E. J., Snyder, A. Z., Dosenbach, N. U. F., & Nicol, G. (2023). Psilocybin desynchronizes brain networks. medRxiv. doi:10.1101/2023.08.22.23294131
51. Singh, S., Botvinnik, A., Shahar, O., Wolf, G., Yakobi, C., Saban, M., Salama, A., Lotan, A., Lerer, B., & Lifschytz, T. (2023). Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder. Transl Psychiatry, 13(1), 164. doi:10.1038/s41398-023-02456-9
52. Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022). Neural Mechanisms and Psychology of Psychedelic Ego Dissolution. Pharmacol Rev, 74(4), 876-917. doi:10.1124/pharmrev.121.000508
53. Thomann, J., Kolaczynska, K. E., Stoeckmann, O. V., Rudin, D., Vizeli, P., Hoener, M. C., Pryce, C. R., Vollenweider, F. X., Liechti, M. E., Duthaler, U. (2024). In vitro and in vivo metabolism of psilocybin's active metabolite psilocin. Front Pharmacol, 15, 1391689. doi:10.3389/fphar.2024.1391689
54. van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bosong, M.G., Batalla, A. (2023). Therapeutic effect of psilocybin in addiction: A systematic review. Front Psychiatry, 14, 1134454. doi:10.3389/fpsyt.2023.1134454
55. Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci, 21(11), 611-624. doi:10.1038/s41583-020-0367-2
56. Wasson, R.G. (1957). Seeking the magic mushroom: A New York banker goes to Mexico's mountains to participate in the age-old rituals of indians who chew strange growths that produce visions. Life 42, 100e120.
57. Wojtas, A., & Gołembiowska, K. (2023). Molecular and Medical Aspects of Psychedelics. Int J Mol Sci, 25(1). doi:10.3390/ijms25010241
58. Woodburn, S. C., Levitt, C. M., Koester, A. M., & Kwan, A. C. (2024). Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors. ACS Chem Neurosci. doi:10.1021/acschemneuro.4c00279
59. Wsół, A. (2023). Cardiovascular safety of psychedelic medicine: current status and future directions. Pharmacol Rep, 75(6), 1362-1380. doi:10.1007/s43440-023-00539-4
60. Xenakis, S. N., & Shannon, S. M. (2024). What is needed for the roll-out of psychedelic treatments? Curr Opin Psychiatry, 37(4), 277-281. doi:10.1097/yco.0000000000000946
61. Yerubandi, A., Thomas, J. E., Bhuiya, N., Harrington, C., Villa Zapata, L., & Caballero, J. (2024). Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open, 7(4), e245960. doi:10.1001/jamanetworkopen.2024.5960
62. Zafar, R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman, L., Wall, M., Nutt, D. J., & Erritzoe, D. (2023). Psychedelic therapy in the treatment of addiction: the past, present and future. Frontiers in Psychiatry, 14, 1183740. https://doi.org/10.3389/fpsyt.2023.1183740
63. Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C., Danias, G., Lepow, L., Yehuda, R. (2024). The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. Curr Neuropharmacol, 22(4), 636-735. doi:10.2174/1570159x22666231027111147